Bendamustine Hydrochloride
Showing 76 - 100 of 2,057
Newly Diagnosed Mantle Cell Lymphoma Trial in Zhengzhou (Rituximab)
Recruiting
- Newly Diagnosed Mantle Cell Lymphoma
-
Zhengzhou, Henan, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhengzh
Aug 17, 2022
Mantle Cell Lymphoma Trial in United States (Ofatumumab (This arm is closed), Ofatumumab + Bendamustine)
Active, not recruiting
- Mantle Cell Lymphoma
- Ofatumumab (This arm is closed)
- Ofatumumab + Bendamustine
-
Basking Ridge, New Jersey
- +5 more
Oct 1, 2021
Diffuse Large B-cell Lymphoma Trial in Worldwide (Rituximab (RTX), Tafasitamab, Bendamustine (BEN))
Active, not recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab (RTX)
- +2 more
-
Anaheim, California
- +157 more
Aug 1, 2022
Diffuse, Large B-Cell, Lymphoma Trial in China (Polatuzumab Vedotin, Bendamustine, Rituximab)
Completed
- Diffuse, Large B-Cell, Lymphoma
- Polatuzumab Vedotin
- +3 more
-
Beijing, China
- +9 more
Jul 7, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed Trial in Tianjin (Zanubrutinib, Fludarabine,
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Zanubrutinib, Fludarabine, cyclophosphamide and rituximab
- Zanubrutinib, bendamustine, rituximab
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Mar 18, 2022
Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Mantle-Cell Trial in Providence (Rituximab, Bendamustine, Vincristine
Active, not recruiting
- Lymphoma, Non-Hodgkin
- +5 more
- Rituximab
- +2 more
-
Providence, Rhode IslandRhode Island Hospital and The Miriam Hospital
Jul 19, 2021
Mantle Cell Lymphoma Trial in Saint Louis (Bendamustine, Rituximab, Acalabrutinib)
Active, not recruiting
- Mantle Cell Lymphoma
- Bendamustine
- +7 more
-
Saint Louis, MissouriWashington University School of Medicine
Feb 2, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide (Pirtobrutinib, Bendamustine, Rituximab)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Pirtobrutinib
- +2 more
-
Los Angeles, California
- +142 more
Jan 10, 2023
Lymphoma, Non-Hodgkin Trial in Worldwide (Copanlisib (BAY80-6946), Placebo, Rituximab)
Active, not recruiting
- Lymphoma, Non-Hodgkin
- Copanlisib (BAY80-6946)
- +7 more
-
Chandler, Arizona
- +199 more
Jan 31, 2023
Non-hodgkin Lymphoma,B Cell Trial in Beijing (Azacytidine, Bendamustine and Piamprizumab)
Recruiting
- Non-hodgkin Lymphoma,B Cell
- Azacytidine, Bendamustine and Piamprizumab
-
Beijing, Beijing, China
- +1 more
May 18, 2021
Mantle Cell Lymphoma Trial in Worldwide (Bendamustine, Rituximab, Ibrutinib)
Active, not recruiting
- Mantle Cell Lymphoma
- Bendamustine
- +3 more
-
Tucson, Arizona
- +201 more
Jan 27, 2023
Refractory/Relapsed Indolent Non-Hodgkin Lymphoma Trial in United States (rituximab, bendamustine, lenalidomide)
Completed
- Refractory/Relapsed Indolent Non-Hodgkin Lymphoma
- rituximab
- +2 more
-
Clive, Iowa
- +16 more
Oct 4, 2019
Lymphoma Trial in Switzerland (rituximab, bendamustine HCl, lenalidomide)
Completed
- Lymphoma
- rituximab
- +2 more
-
Baden, Switzerland
- +15 more
May 14, 2019
Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,
Not yet recruiting
- Prostate Carcinoma
- +3 more
- Bendamustine
- +12 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 17, 2023
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto
Not yet recruiting
- Multiple Sclerosis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Palo Alto, CaliforniaStanford Multiple Sclerosis Center
Nov 13, 2023
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in United Kingdom (Epcoritamab, Lenalidomide, Rituximab)
Not yet recruiting
- Relapsed Follicular Lymphoma
- Refractory Follicular Lymphoma
- Epcoritamab
- +10 more
-
Aberdeen, United Kingdom
- +24 more
Apr 28, 2023
Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in
Not yet recruiting
- Metastatic Colorectal Adenocarcinoma
- +5 more
- Bendamustine
- +11 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 12, 2023
Lymphatic Diseases Trial in Italy (Brentuximab Vedotin, Bendamustine)
Terminated
- Lymphatic Diseases
- Brentuximab Vedotin
- Bendamustine
-
Bologna, BO, Italy
- +4 more
May 26, 2021
Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma Trial in Worldwide (Oral azacitidine,
Active, not recruiting
- Relapsed Angioimmunoblastic T-Cell Lymphoma
- Refractory Angioimmunoblastic T-cell Lymphoma
- Oral azacitidine
- +3 more
-
Graz, Austria
- +33 more
Aug 24, 2022
Relapsed or Refractory DLBCL Trial in United States (Selinexor, Rituximab, Bendamustine)
Suspended
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Selinexor
- +9 more
-
Tucson, Arizona
- +17 more
Jan 24, 2023
Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma Trial in United States (Duvelisib, Placebo,
Withdrawn
- Indolent Non-Hodgkin's Lymphoma
- +3 more
- Duvelisib
- +3 more
-
Plainville, Connecticut
- +6 more
Mar 15, 2021